MONTREAL, QUEBEC–(Marketwired – Jun 16, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”) announced today that each director nominee listed in the Management Information Circular dated May 13, 2016 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec.

The details of the election are as follows:

James C. Gale Elected 71,554,988 99.11% 640,829 0.89%
Jonathan Ross Goodman Elected 72,146,127 99.93% 49,690 0.07%
Meir Jakobsohn Elected 72,138,037 99.92% 57,780 0.08%
Robert N. Lande Elected 71,556,188 99.11% 639,629 0.89%
Ed Schutter Elected 72,067,904 99.82% 127,913 0.18%
Sylvie Tendler Elected 72,041,935 99.79% 153,882 0.21%

The results of the final votes regarding all matters subject to a vote during the Annual Meeting will be made available on SEDAR (

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at or

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.